Adamas Pharmaceuticals’ Parkinson’s drug Gocovri has a new indication as an adjunctive treatment for levodopa/carbodopa in patients with Parkinson’s disease experiencing ‘off’ episodes.
US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological d
Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion.
The FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects of standard therapy and help prevent “off”
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
